𝔖 Bobbio Scriptorium

✦ LIBER ✦

Short- and long-term briakinumab efficacy in moderate to severe psoriasis patients with prior TNF antagonist exposure: Subanalysis of a 52-week phase III trial and open-label extension

Book ID: 116589057
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 49 KB
Volume: 66
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2011.11.851

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of briakinumab in mo

Efficacy and safety of briakinumab in moderate to severe psoriasis patients with prior failure to TNF antagonist: Subanalysis of a 52-week phase III trial and open-label extension

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Short- and long-term efficacy and safety

Short- and long-term efficacy and safety of adalimumab in a pivotal phase III study in adult patients with moderate to severe chronic plaque psoriasis

📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Efficacy and safety of efalizumab in adu

Efficacy and safety of efalizumab in adults with moderate to severe plaque psoriasis and hand and foot involvement: A prospective, 24-week, open-label phase IIIb/IV clinical trial in patients from Latin America

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Long-term safety and efficacy of linagli

Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension

✍ R. Gomis; D. R. Owens; M.-R. Taskinen; S. Del Prato; S. Patel; A. Pivovarova; A. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB